Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.

ABSTRACT:

Background

Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies are well understood as these lead to decreased antibody production. Most studies regarding immunodeficiency in B-NHLs were conducted with multiple myeloma and chronic lymphocytic leukemia patients. As these studies not always represent the general population we collected and analyzed real world data from patients with indolent lymphomas and a control group (CG).

Results

Patients with B-NHLs undergoing therapy or who were regularly monitored in a watch and wait approach had, over the time of one year, an increased rate of

SUBMITTER: Lutz C 

PROVIDER: S-EPMC9833869 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature